Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat Combination Regimen in Relapsed/Refractory Peripheral T Cell Lymphoma
NCT07724782Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in peripheral T-cell lymphoma (PTCL), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT07724782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724782.